Sarepta Therapeutics, Inc.
SRPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,901,979 | $1,243,336 | $933,013 | $701,887 |
| % Growth | 53% | 33.3% | 32.9% | – |
| Cost of Goods Sold | $319,099 | $150,343 | $139,989 | $97,049 |
| Gross Profit | $1,582,880 | $1,092,993 | $793,024 | $604,838 |
| % Margin | 83.2% | 87.9% | 85% | 86.2% |
| R&D Expenses | $804,522 | $877,387 | $877,090 | $771,182 |
| G&A Expenses | $557,872 | $453,271 | $436,821 | $282,660 |
| SG&A Expenses | $557,872 | $481,871 | $451,421 | $282,660 |
| Sales & Mktg Exp. | $0 | $28,600 | $14,600 | $0 |
| Other Operating Expenses | $2,405 | $1,559 | $714 | $10,706 |
| Operating Expenses | $1,364,799 | $1,360,817 | $1,329,225 | $1,064,548 |
| Operating Income | $218,081 | -$267,824 | -$536,201 | -$459,710 |
| % Margin | 11.5% | -21.5% | -57.5% | -65.5% |
| Other Income/Exp. Net | $42,693 | -$252,274 | -$153,762 | $40,762 |
| Pre-Tax Income | $260,774 | -$520,098 | -$689,963 | -$418,948 |
| Tax Expense | $25,535 | $15,879 | $13,525 | -$168 |
| Net Income | $235,239 | -$535,977 | -$703,488 | -$418,780 |
| % Margin | 12.4% | -43.1% | -75.4% | -59.7% |
| EPS | 2.47 | -5.8 | -8.03 | -5.15 |
| % Growth | 142.6% | 27.8% | -55.9% | – |
| EPS Diluted | 2.34 | -5.8 | -8.03 | -5.15 |
| Weighted Avg Shares Out | 95,075 | 92,398 | 87,559 | 81,262 |
| Weighted Avg Shares Out Dil | 107,875 | 92,398 | 87,559 | 81,262 |
| Supplemental Information | – | – | – | – |
| Interest Income | $71,767 | $85,969 | $27,723 | $511 |
| Interest Expense | $18,391 | $22,010 | $53,248 | $63,525 |
| Depreciation & Amortization | $53,891 | $58,892 | $54,599 | $38,017 |
| EBITDA | $333,056 | -$439,196 | -$582,116 | -$317,406 |
| % Margin | 17.5% | -35.3% | -62.4% | -45.2% |